4D Molecular Therapeutics

  • About
    • Company Overview
    • Purpose AND Strategy
    • LEADERSHIP TEAM
    • BOARD OF DIRECTORS
    • CONTACT US
  • Technology
    • GENE THERAPY
    • Conventional Vectors
    • 4DMT Therapeutic Vector Evolution
    • SCIENTIFIC PRESENTATIONS
  • Product Pipeline
    • Pipeline Overview
    • Ophthalmology
    • Cardiology
    • Pulmonology
  • Patients
    • Overview
    • Clinical Trials
      • XLRP 4D-125
      • XLRP Natural History
      • CHM 4D-110
      • Wet AMD 4D-150
      • Fabry 4D-310
      • CF 4D-710
    • Advocacy Partners
    • Patient Stories
    • Resources
  • Investors
    • Overview
    • Events and Presentations
    • Press Releases
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
  • Careers and Culture
    • Overview and Openings
    • Competitive Compensation
    • BENEFITS, BALANCE and WELL-BEING
    • GROWTH AND DEVELOPMENT
    • CULTURE and COMMUNITY
  • Home
  • Terms of Use
Menu

1 billion possibilities
for a cure

Boldly Innovating to Unlock
the Full Potential of Gene Therapy
for Countless Patients

VECTOR &
PROMOTER
TECHNOLOGY THAT
DELIVERS

More

LEARN ABOUT
OUR XLRP
clinical TRIAL

More

A DIVERSE
PRODUCT
PIPELINE

More

PATIENT
ADVOCACY AND
PERSONAL STORIES

More

In The News

August 2022

4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update

more

June 2022

4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences

more

See how we’re innovating to unlock the full potential of gene therapy

Learn what differentiates our optimized, proprietary, targeted vectors

Share Linkedin Facebook
  • About
    • Company Overview
    • Purpose AND Strategy
    • LEADERSHIP TEAM
    • BOARD OF DIRECTORS
    • CONTACT US
  • Technology
    • GENE THERAPY
    • Conventional Vectors
    • 4DMT Therapeutic Vector Evolution
    • SCIENTIFIC PRESENTATIONS
  • Product Pipeline
    • Pipeline Overview
    • Ophthalmology
    • Cardiology
    • Pulmonology
  • Patients
    • Overview
    • Clinical Trials
      • XLRP 4D-125
      • XLRP Natural History
      • CHM 4D-110
      • Wet AMD 4D-150
      • Fabry 4D-310
      • CF 4D-710
    • Advocacy Partners
    • Patient Stories
    • Resources
  • Investors
    • Overview
    • Events and Presentations
    • Press Releases
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
  • Careers and Culture
    • Overview and Openings
    • Competitive Compensation
    • BENEFITS, BALANCE and WELL-BEING
    • GROWTH AND DEVELOPMENT
    • CULTURE and COMMUNITY
  • Home
  • Terms of Use
© 2022 4D Molecular Therapeutics, All Rights Reserved